Business
dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners
Press Release dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, today announces it has entered into an agreement with CVC, a leading global private markets manager, to divest its Animal Nutrition & Health (“ANH”) business for an enterprise value of about €2.2 billion, which includes an earnout of up to €0.5 billion. dsm-firm
About this update from Dsm-firmenich Ag
[{"type":"image","alt":"dsm-firmenich","displaySize":"","headline":null,"caption":"dsm-firmenich","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/9b415d4a2865afc6fd1cf942611724d8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mMYFeKUNdZU9mGc.nThqBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/9b415d4a2865afc6fd1cf942611724d8","width":300,"height":58}},"lazy":false},{"type":"text","content":"Press Release","length":13,"tagName":"p"},{"type":"text","content":"dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners","length":97,"tagName":"p"},{"type":"text","content":"Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026","length":69,"tagName":"p"},{"type":"text","content":"dsm-firmenich, innovators in nutrition, health, and beauty, today announces it has entered into an agreement with CVC, a leading global private markets manager, to divest its Animal Nutrition & Health (“ANH”) business for an enterprise value of about €2.2 billion, which includes an earnout of up to €0.5 billion. dsm-firmenich will retain a 20% equity stake in the divested ANH Companies, in partnership with CVC.","length":418,"tagName":"p"},{"type":"text","content":"This transaction follows the sale of the Feed Enzymes activities to Novonesis for €1.5 billion in 2025 and marks the final strategic step for dsm-firmenich to become a fully focused consumer company active in nutrition, health, and beauty. The total enterprise value of ANH, including the prior sale of the Feed Enzymes activities, represents €3.7 billion.","length":356,"tagName":"p"},{"type":"text","content":"The company intends to launch a new share repurchase program to buy back ordinary shares with an aggregate market value of €0.5 billion and reduce its issued capital. The program is planned to commence in Q1 2026.","length":213,"tagName":"p"},{"type":"text","content":"In addition, dsm-firmenich aims to deliver consistent and sustainable dividends to its shareholders. To achieve this, the company has adopted a ‘stable to preferably rising’ dividend policy, reflecting the company’s commitment to long-term value creation. Under this policy, dsm-firmenich aims to maintain a stable dividend of €2.50 per ordinary share and...